Phio Pharmaceuticals Corporation (PHIO) ニュース

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form RW - Registration Withdrawal Request

Form S-3 - Registration statement under Securities Act of 1933

Form 424B5 - Prospectus [Rule 424(b)(5)]

Phio Pharmaceuticals Secures New Investor

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical...

Form 8-K - Current report

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical...

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May...

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762...

Form 8-K - Current report